IL7 and myeloid sarcoma: Thus our analysis suggests that the effect of soluble IL-7R on MS aetiology may be mediated by modulation of lymphocyte activation as measured by RE-LYMPH#, consistent with the role of IL-7R/IL-7 as an efficacious target for the treatment of MS50.